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Effects of Novel Growth Hormone Secretagogues on Growth Hormone
Secretion in Farm Animals
Abstract
The requirement for growth hormone (GH) secretion by the anterior pituitary gland in beef calves is
demonstrated by a complete lack of long bone-growth and muscle accretion after hypophysectomy (surgical
removal of the pituitary gland). When the connecting link (hypophyseal stalk) to the basal region
(hypothalamus) of the brain is surgically severed, long bone growth and body weight gain are greatly limited
compared with sham-operated controls. This limited growth results from obliteration of episodic GH
secretion and reduced basal blood concentration of the hormone compared with sham-operated controls.
Thus, the hypophyseal stalk-transected (HST) calf provides an appropriate model to determine mechanisms
by which hypothalamic neuropeptides from the brain regulate GH secretion, and thereby growth in the young
calf. Neuropeptides have been isolated and characterized in bovine hypothalamus that stimulate GH secretion
(GH-releasing hormone [GHRH]) or factor [GHRF] and inhibit GH secretion (GH release-inhibiting
hormone [GHRIH] or somatostatin [SRIH]). A dose of .067 micrograms of GHRF per kilogram of body
weight injected intravenously in HST calves abruptly increased plasma GH concentration to 55 nanograms
per milliliter from the control period mean of 5 nanograms per milliliter. HST calves then were infused
intravenously with .033 and .067 microgram somatostatin per kilogram of body weight, during which a pulse
injection of .067 microgram of GHRF was administered. GH increase was limited to 9 and 5 micrograms per
kilogram body weight during the .033- and .067 microgram SRIH infusions after GHRF; no GH rebound was
observed after the SRIH was discontinued. GHRF from humans contains 40 to 44 amino acids. Rat
hypothalamic GHRF analogs containing 29 to 32 amino acids elicited dose-dependent GH peak release in
these HST calves. In 1977, Bowers and Monomy isolated novel GH releasing peptides consisting of only six
amino acids; they caused GH release by isolated pituitary cells in culture and acute GH release when
administered intravenously. We recently have utilized a novel nonpeptidyl GH secretagogue of low molecular
weight in the pig to determine its mechanisms of action within the central nervous system.
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Summary
The requirement for growth hormone (GH) secretion
by the anterior pituitary gland in beef calves is
demonstrated by a complete lack of long bone-growth
and muscle accretion after hypophysectomy (surgical
removal of the pituitary gland). When the connecting
link (hypophyseal stalk) to the basal region
(hypothalamus) of the brain is surgically severed,
long bone growth and body weight gain are greatly
limited compared with sham-operated controls. This
limited growth results from obliteration of episodic
GH secretion and reduced basal blood concentration
of the hormone compared with sham-operated con-
trols.
Thus, the hypophyseal stalk-transected (HST) calf
provides an appropriate model to determine mecha-
nisms by which hypothalamic neuropeptides from
the brain regulate GH secretion, and thereby growth
in the young calf. Neuropeptides have been isolated
and characterized in bovine hypothalamus that
stimulate GH secretion (GH-releasing hormone
[GHRH]) or factor [GHRF] and inhibit GH secretion
(GH release-inhibiting hormone [GHRIH] or
somatostatin [SRIH]). A dose of .067 micrograms of
GHRF per kilogram of body weight injected
intravenously in HST calves
abruptly increased plasma GH concentration to 55
nanograms per milliliter from the control period
mean of 5 nanograms per milliliter. HST calves then
were infused intravenously with .033 and .067
microgram somatostatin per kilogram of body weight,
during which a pulse injection of .067 microgram of
GHRF was administered. GH increase was limited to
9 and 5 micrograms per kilogram body weight
during the .033- and .067 microgram SRIH infusions
after GHRF; no GH rebound was observed after the
SRIH was discontinued. GHRF from humans
contains 40 to 44 amino acids. Rat hypothalamic
GHRF analogs containing 29 to 32 amino acids
elicited dose-dependent GH peak release in these
HST calves.
In 1977, Bowers and Monomy isolated novel GH
releasing peptides consisting of only six amino acids;
they caused GH release by isolated pituitary cells in
culture and acute GH release when administered
intravenously. We recently have utilized a novel
nonpeptidyl GH secretagogue of low molecular
weight in the pig to determine its mechanisms of
action within the central nervous system.
Introduction
Hypothalamic regulation of GH secretion is mediated
by a stimulatory factor, GH-releasing factor (GHRF), and
an inhibitory factor, GH-release-inhibitory hormone,
somatostatin (SRIH). Intravenous administration of
GHRF causes a pulse release of GH into the circulating
blood, similar to that occurring during endogenous GH
secretion. It has been suggested that the pattern of GH
secretion, frequency and amplitude of GH spikes, is im-
portant in the regulation of growth in the laboratory rat
but may not be important for other species such as cattle.
The objective of this study was to determine the effect of
GHRF analogs on the secretion of GH in prepuberal
calves and a novel GH secretagogue on GH secretion in
the prepuberal pig. The overall goal is to gain a better
understanding of the mechanisms by which these
neuropeptides effect central nervous system regulation of
GH secretion in farm animals.
Materials and Methods
Animals
Thirteen Aberdeen Angus calves from 6 to 10 months
old, weighing 105-232 kilograms, were subjected to hy-
pophysectomy (n = 5), hypophyseal stalk transection (n
= 4), or cranial sham operation (n = 4). Body weight
change and the histology of endocrine gland development
were determined. Crossbred beef heifers (4 months old,
111 –  8 kilograms body weight [mean –  standard error])
were subjected to hypophyseal stalk transection (n = 5)
or sham operation control (n = 2). The calves were fitted
with a jugular cannula for repeat blood sampling and
hormone administration. The effects of intravenous injec-
tion of human pancreatic GHRF, [hpGHRF], analogs of
rat hypothalamic GHRF, [Nle27]rhGHRF(1-29)NH2 and
rhGHRF(1-32)OH, thyrotropin releasing hormone (TRH),
and somatostatin (SRIH) on plasma GH concentrations
were determined. Finally, the effects of a nonpeptidyl GH
secretagogue, L-692,585, on GH secretion were deter-
mined in hypophyseal stalk transected (n = 3) and sham
operated (n = 3) castrated male Yorkshire pigs (approxi-
mately 32 kilograms body weight). The pigs were fitted
with a jugular cannula for repeat blood sampling.
Hormone Radioimmunoassays
Validated radioimmunoassays for GH, adrenocor-
ticotropic hormone (ACTH), cortisol, and prolactin were
carried out in duplicate plasma samples.
Statistical Analysis
The experimental units were the individual calves or
pigs. Dose-response data were analyzed using a Latin
square design; other data were analyzed using Student's t
test for comparison among treatment groups.
Results and Discussion
After hypophyseal stalk transection, the weight of the
pituitary gland decreased in calves (p < .005) compared
with sham-operated controls (.19 –  .01 versus .57 –  .07
grams per 100 kilograms body weight; mean –  standard
error). Histological examination of the pituitary revealed
large infarcts in the pars distalis and normal-appearing
pars nervosa and pars intermedia. Growth was inhibited
in calves after HST or hypophysectomy. Body-weight in-
crease in calves after hypophyseal stalk transection (.089
kilograms per day) or hypophysectomy (-.061 kilograms
per day) was reduced markedly compared with that found
in sham-operated calves (.467 kilograms per day) or in
unoperated calves (.594 kilograms per day) during a
period of 90 days. Growth during a prolonged period after
hypophysectomy (calves 14 and 16) or after hypo-physeal
stalk transection (calf 89) was limited severely (p < .01)
as compared with that found in four sham-operated calves
and nine unoperated controls (Figure 1).
Figure 1. Growth rates in Aberdeen Angus calves
during prolonged periods after hypophysectomy
in bull calf 16 (Ÿ, .099 kilograms per day) and in
heifer calf 14 (_, .288 kilograms per day), after
hypophysial stalk transection of heifer calf 89
( ° , .167 kilograms per day) as compared with
those found in sham-operated calves (o, .600
kilograms per day) and in unoperated calves (l,
.641 kilograms per day). (Anderson, Am. J.
Physiol .  232:E497-E503, 1977.)
In initial studies with GH-releasing factor or hormone
(GHRF or GHRH), we established a dose-dependent
acute release of GH into peripheral blood of intact
crossbred beef heifer calves (four months old; 111
kilograms body weight). Animals received an intravenous
injection of human pancreatic GH-releasing factor
[hpGHRF(1,40)OH] and a GHRH analog, Nle27 rat hypo-
thalamic GHRF [Nle27rGHRF(1,29)NH2] dissolved in
0.1% acetic acid and then diluted with a sterile buffer
solution. The buffer was physiological saline (0.818%)
containing 0.01 molar Na2PO4/H2O, pH 7.0;0.01% ascor-
bic acid; and 1% bovine serum albumin. An indwelling
jugular vein cannula was inserted for repeat blood sam-
pling and hormone injection. Plasma GH increased in a
dose-dependent manner, with a peak of GH occurring
between 5 and 15 minutes after injection of hpGHRF
(Figure 2).
Figure 2. Mean concentrations of plasma GH in
crossbred beef heifers in response to iv
injections of 0, .01, .033, .067 and .1 mg
hpGHRF (1,40)OH/kg body wt (n=5). The dose of
hpGHRF is indicated above the arrow at the time
of administration. To indicate representative SE
at baseline and peak concentrations, the
samples 10 min before and after injection of
hpGHRF have SE marked by the bars. (Plouzek
et al., Proc. Soc. Exp. Biol. Med. 188:198-205,
1 9 8 8 . )
GH levels during the 20-minute period after injection of
0.067 (p < .05) and 0.1 microgram hpGHRF per kilogram
body weight (p < .025) were greater than controls,
whereas 0.01 and 0.033 micrograms hpGHRF per kilo-
gram body weight were similar to controls. Five-month-
old heifers receiving GHRF every 3 hours for 42 hours
responded to 50% of the GHRF injections (Figure 3),
whereas a greater degree of responses (77%) was
observed in three-and-a-half-month-old bull calves given
GHRF every 4 hours for 10 days. The amplitude of the
GH response to GHRF may have been related to feeding.
The GH response to GHRF was greater before feeding
than after feeding (Figure 3).
Figure 3. The average plasma GH concentrations
of crossbred beef heifers receiving 0 or .067 mg
hpGHRF(1,40)OH/kg body wt at 3-h intervals for
42 h. The thick line illustrates the response of
animals receiving hpGHRF (n=5), and the thin
line illustrates the plasma response of animals
receiving buffer without hpGHRF (n=5). To
represent SE before hpGHRF injection and
during the peak response of GH after hpGHRF
injection, SE are shown by the bars for samples
40 min before hpGHRF injection and 10 min after
injection. Times of feeding and hpGHRF
administration are indicated by the arrows.
(Plouzek et al., Proc. Soc. Exp. Biol. Med.
188:198-205, 1988.)
Effects of multiple injections of Nle27 rGHRF(1,29)NH2
for 10 days in bull calves are shown in Table 1.
The mean GH response in animals given rGHRF was
25 nanograms per milliliter (p < .05), compared with 7
nanograms per milliliter plasma in the controls. Somato-
medin-C (insulin-like growth factor-I [IGF-I]), insulin,
triiodothyronine, thyroxine, and cortisol concentrations
were not changed with administration of rGHRF. Thus,
the overall results indicate that intact prepubertal bull
and heifer calves were responsive to GHRF administered
as either discrete or multiple intravenous injections.
The neurohypophyseal link between the hypothala-
mus and the pituitary is essential for conveying these
releasing and inhibiting hormones. After surgical hypoph-
yseal stalk transection (HST), normal episodic secretion
of GH is abolished in cattle and pigs, and these animals
have depressed growth rates. HST calves and pigs serve
as useful models to study the isolated effects of releasing
and inhibiting substances on pituitary hormone secretions.
Seven crossbred beef heifers (four months old, 111 –  8
kilograms body weight ( –  standard error) were fitted with
an indwelling jugular cannula and subjected to either
HST or cranial sham operation control (SOC). After the
hypophyseal stalk was severed, a nylon disc (8.0
millimeters diameter and .45 millimeter thickness) was
inserted between the severed ends of the tubular stalk to
prevent regeneration between the hypothalamus and
pituitary gland. In seven calves subjected to either HST
or SOC, the plasma GH levels during surgery and
immediately in the postoperative recovery period are
depicted in Figure 4.
Table 1. Effect of multiple injections of Nle2 7
rGHRF (1,29)NH2 on plasma hormone means over
10 days in bull calves.
aMean of 20, 10 and 1 min before rGHRF
injection.
bMean of 5, 10, 15, and 20 min after rGHRF
injection.
cMean significantly different (p < .05) from
corresponding control mean.
dMean of 40 and 60 min after rGHRF injection.
(Plouzek et al., Proc. Soc. Exp. Biol. Med.
188:198-205, 1988.)
GH secretion during the preanesthesia period, 9 –  3.9
nanograms per milliliter (mean values from -345 to -195
minutes), was variable but tended to decrease just
preceding anesthesia. GH returned to presurgery baseline
concentrations at 3-4 hours in the SOC calves after
anesthesia was removed; however, HST calves did not
resume GH concentrations similar to those observed
before surgery (SOC, 10 –  1.8 versus HST 3 –  1.0
nanograms per milliliter; p < .05). The HST calves
responded to .067 and .133 micrograms hpGHRF per
kilogram body weight with a rapid increase in plasma
GH, which peaked within 10-20 minutes and then
declined to preinjection concentrations within 60 minutes
(Figure 5). After HST, all calves responded to 100% of
the hpGHRF injections. This was similar to their
responses before surgery in which the calves responded to
80% of hpGHRF challenges. Infusion of 2 and 4 micro-
grams SRIH (kilogram body weight per hour) or
equivalent to .033 and .067 microgram SRIH per kilogram
body weight per minute depressed GH release in response
to an administered bolus of .067 micrograms hpGHRF per
kilogram body weight (Figure 6). GH levels 20 minutes
after hpGHRF were 9 –  1.6 nanograms per milliliter
rGHRF Control SE
                                                                                                                                         
GH (ng/ml)a 6.5 8.7 1.5
GH (ng/ml)b 25.1c 7.0 8.0
GH (ng/ml)d 9.8 7.8 1.8
Sm-C (nmole/liter) 8.1 6.6 2.4
Insulin (ng/ml) .54 .51 .12
Triiodothyronine (ng/dl) 1.31 1.34 .22
Thyroxine (mg/dl) 7.7 7.4 1.1
Cortisol (mg/dl) 2.2 1.8 .3
during infusion of .0333 microgram SRIH and 5 –  .4
nanograms per milliliter during infusion of .067 micro-
gram SRIH. The changes in plasma GH during the infu-
sion of either dose of SRIH were not significantly differ-
ent in any part of the experiment or between doses of
SRIH. After the infusion of SRIH were stopped, GH
concentrations remained stable.
Figure 4. Plasma GH concentrations in beef
calves before and after surgery are illustrated.
The GH response indicated by the open circles
illustrates the period before surgical
intervention, which is indicated by the open
arrow (n=7). Plasma GH after HST is illustrated
by closed triangles (n=5), and GH after SOC is
indicated by squares (n=2). Values are means –
SE. SE bars for samples taken 2 and 3 h after
surgery are within the symbol. (Plouzek et al.,
Proc. Soc. Exp. Biol. Med. 189:158-167, 1988.)
Our results indicate that intravenous injection of the
brain neuropeptide GHRH causes acute peak release of
GH into the peripheral blood of intact bull and heifer
calves. After hypophysial stalk transection, the calves
remain acutely responsive to GHRF challenge, releasing
similar amounts of GH into peripheral blood within a few
minutes. In contrast, constant infusion of somatostatin-14
(SRIH) during a 2-hour period in HST calves greatly
inhibits GH release during a GHRH challenge. Thus, the
HST calf provides a unique model to abolish episodic GH
release and to show that GHRF administration can direct-
ly stimulate GH release by the pituitary gland.
In 1977, the first peptides of the GH-releasing
peptide (GHRP) series were discovered. They were
derivatives of the pentapeptide Met-enkephalin and had
the structures Tyr-DTrp-Gly-Phe-Met-NH2 or Tyr-DPhe-
Gly-Phe-Met-NH2. Several analogs with ability to
specifically cause GH release both in vivo and in vitro
have been synthesized. A particularly potent
hexapeptide, His-DTrp-Ala-Trp-DPhe-Lys-NH2, causes
GH release and hypothalamic binding activity 1000 times
greater than the original GHRPs. With a burgeoning
interest in this family of GHRPs, novel nonpeptidyl GH
secretagogues recently have been developed consisting
of substituted benzolactams with high biological potency
to cause GH-release. We have used one of these potent
benzolactam analogs, L-692,585, to determine central
mechanisms of its GH releasing action in the young
castrate male pig subjected to hypophyseal stalk
transection or sham operation control. Before cranial
surgery, GH concentration averaged 5 or 6 nanograms per
milliliter plasma (Table 2).
Figure 5. Plasma GH concentrations in HST
calves in response to 0, .067, and .133 mg(1-
40)-OH hpGHRF/kg body wt are illustrated by the
closed triangles (n=5). For comparison, the
response to .067 and .133 mg(1-40)-OH
hpGHRF/kg body wt before surgery in these
animals is indicated by the open circles in the
left and right panels, respectively. The GH
response to .067 mg hpGHRF is shown in the left
panel, and the right panel indicates the effect of
the more concentrated dose of hpGHRF. Arrows
indicate the time of vehicle or hpGHRF
administration. Values are means –  SE. (Plouzek
et al., Proc. Soc. Exp. Biol. Med. 189:158-167,
1 9 8 8 . )
Intravenous injection of L-692,585 acutely increased
GH levels 15-fold, whereas intravenous injection of
hGHRF caused only a 2- to 5-fold increase in GH plasma
levels. The combined treatment of L-692,585 with
hGHRF caused a 28-fold increase in GH concentration
compared with the control period. After HST, L-692,585
alone or combined with hGHRF caused a similar
immediate increase in plasma GH concentration. Basal
cortisol concentrations were reduced in the HST pigs
relative to the SOC group. GHRF did not significantly
increase cortisol levels when administered alone or
further increase L-692,585-induced response.Overall, the
results indicate that coadministration of GHRF with L-
692,585 allows the isolated pituitary gland to release GH
maximally. Transection of the hypothalamo-pituitary
stalk markedly decreased the GH and cortisol response to
L-692,585, but did not reduce the synergistic GH
response to L-692,585 plus hGHRF coadministration.
Table 2. Effect of hypothalamo-pituitary stalk
transection in the pig on GH secretory activity
of L-692,585.
*.1 mg/kg body weight
**.02 mg/kg body weight
(Hickey et al. Proceedings of 76th Annu. Mtg. of
the Endocrine Society, Anaheim, Calif., 1994,
Abstract 661.)
Implications
Episodic and basal secretion of growth hormone
by the pituitary gland in calves and pigs is essential
for normal growth and development; pituitary
gland removal abruptly limits growth in these
species. When the neurohypophyseal link between
the pituitary gland and hypothalamus at the base
of the brain is severed, episodic GH secretion is
abolished and growth impaired. The administra-
tion of brain neuropeptides that stimulate (i.e.,
GHRFs, GHRPs, and nonpeptidyl GH secretagog-
ues) and inhibit (i.e., somatostatin, SRIH, and
related analogs) GH secretion in HST and intact
calves and pigs provide novel models to further
our understanding of central nervous system regu-
lation of growth and development in farm animals.
Figure 6. Mean concentrations of plasma GH in
HST calves during iv infusion of 2 and 4 mg
somatostatin(SS)-14 (SRIH)/kg body wt per h) or
equivalent to .033 and .067 mg SRIH/kg body wt
per min and injected with .067 mg(1-40)-OH
hpGHRF/kg body wt are illustrated by closed
triangles (n=2). The same animals' response to
these hormone treatments before surgical
intervention is shown by the open circles.
Arrows indicate the time of hpGHRF injections,
and the hatched areas illustrate the period of
SRIH infusion. (Plouzek et al., Proc. Soc. Exp.
Biol. Med. 189:158-167, 1988.)
    
  GH in peripheral plasma
                                      (ng/ml)           
Item SOC HST Probability
                                                                                                                  
Yorkshire barrows, n 3 3
Presurgery (d -7 to -3)
Control period 6.4 5.2
L-692,585* 101 71
hGHRF** 13 25 p < .01
L-692,585 + hGHRF 171 174
Postsurgery (d +3 to +9)
Control period 6.7 5.8
L-692,585* 79 14 p < .005
hGHRF** 13 27 p = .05
L-692,585 + hGHRF 115 94

